AnaptysBio (ANAB) Expected to Announce Earnings on Monday

Key Points

• Q1 2026 results due Monday, May 4: AnaptysBio is expected to report earnings before the open on May 4 with analysts forecasting EPS of ($0.8996) and revenue of $23.039 million, and the company’s earnings call is scheduled for May 8 at 4:00 PM ET.
• Mixed recent financials and outlook: The company beat estimates in its last reported quarter (EPS $1.58, revenue $108.25M), but analysts now project roughly -$3 EPS for the current fiscal year and -$2 for the next fiscal year.
• Corporate actions and market view: Management initiated a sizable share buyback program in late March and insiders have been net sellers recently (CEO sold 17,679 shares); the stock has a market cap of ~$1.69B and a consensus analyst rating of "Moderate Buy" with an average target of $75.50.

AnaptysBio (NASDAQ:ANAB - Get Free Report) is anticipated to post its Q1 2026 results before the market opens on Monday, May 4th. Analysts expect AnaptysBio to post earnings of ($0.8996) per share and revenue of $23.0390 million for the quarter. Individuals may review the information on the company's upcoming Q1 2026 earning report for the latest details on the call scheduled for Friday, May 8, 2026 at 4:00 PM ET.

AnaptysBio (NASDAQ:ANAB - Get Free Report) last posted its quarterly earnings data on Tuesday, March 3rd. The biotechnology company reported $1.58 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.89 by $0.69. The business had revenue of $108.25 million during the quarter, compared to the consensus estimate of $87.09 million. AnaptysBio had a negative return on equity of 1,101.24% and a negative net margin of 5.64%. On average, analysts expect AnaptysBio to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

AnaptysBio Stock Performance

NASDAQ:ANAB opened at $58.88 on Monday. The company has a market cap of $1.69 billion, a PE ratio of -113.23 and a beta of 0.40. AnaptysBio has a 52-week low of $17.11 and a 52-week high of $73.30. The stock has a 50-day simple moving average of $60.00 and a 200 day simple moving average of $48.87.

AnaptysBio declared that its board has initiated a share buyback program on Friday, March 27th that permits the company to buyback $100,000.00 billion in shares. This buyback authorization permits the biotechnology company to repurchase up to 5,352,316.2% of its stock through open market purchases. Stock buyback programs are typically an indication that the company's board believes its shares are undervalued.

Insider Buying and Selling at AnaptysBio

In other AnaptysBio news, CEO Daniel Faga sold 17,679 shares of the firm's stock in a transaction that occurred on Friday, March 27th. The stock was sold at an average price of $61.61, for a total value of $1,089,203.19. Following the completion of the transaction, the chief executive officer directly owned 495,965 shares in the company, valued at $30,556,403.65. This trade represents a 3.44% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Eric J. Loumeau sold 10,000 shares of the firm's stock in a transaction that occurred on Wednesday, February 11th. The shares were sold at an average price of $54.00, for a total value of $540,000.00. Following the completion of the transaction, the insider owned 12,835 shares of the company's stock, valued at approximately $693,090. This represents a 43.79% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 48,324 shares of company stock worth $2,787,594 over the last ninety days. 33.50% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the business. State Street Corp boosted its stake in shares of AnaptysBio by 20.6% during the 4th quarter. State Street Corp now owns 1,053,474 shares of the biotechnology company's stock worth $51,072,000 after acquiring an additional 180,042 shares during the period. Affinity Asset Advisors LLC bought a new position in shares of AnaptysBio during the 4th quarter worth approximately $21,559,000. Goldman Sachs Group Inc. boosted its stake in shares of AnaptysBio by 20.9% during the 4th quarter. Goldman Sachs Group Inc. now owns 398,914 shares of the biotechnology company's stock worth $19,339,000 after acquiring an additional 69,094 shares during the period. Jacobs Levy Equity Management Inc. boosted its stake in shares of AnaptysBio by 2.7% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 378,452 shares of the biotechnology company's stock worth $11,588,000 after acquiring an additional 10,005 shares during the period. Finally, Arrowstreet Capital Limited Partnership boosted its stake in shares of AnaptysBio by 145.6% during the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 370,458 shares of the biotechnology company's stock worth $11,343,000 after acquiring an additional 219,648 shares during the period.

Analyst Ratings Changes

A number of research analysts recently issued reports on the company. Stifel Nicolaus increased their price objective on AnaptysBio from $56.00 to $85.00 and gave the stock a "buy" rating in a report on Thursday, March 5th. Wedbush increased their price objective on AnaptysBio from $60.00 to $75.00 and gave the stock an "outperform" rating in a report on Thursday, March 12th. Barclays decreased their price objective on AnaptysBio from $79.00 to $63.00 and set an "overweight" rating for the company in a report on Wednesday, April 22nd. UBS Group decreased their price target on AnaptysBio from $90.00 to $60.00 and set a "buy" rating for the company in a research note on Tuesday, April 21st. Finally, HC Wainwright restated a "buy" rating and issued a $66.00 price target on shares of AnaptysBio in a research note on Monday, March 30th. Nine analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, AnaptysBio has a consensus rating of "Moderate Buy" and an average price target of $75.50.

About AnaptysBio

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company's technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company's pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.